GlassScriptPhysician profile
Philippe R Chain
NPI 1265629042
$3,792.66
in general payments reported to CMS, 2019-2025
30 companies · $168 in 2025
The $168 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226 · 2020: $264 · 2021: $1,076 · 2022: $819 · 2023: $641 · 2024: $598 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,388 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,387.59 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,228.53 | 2019-2024 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $351.02 | 2019-2022 | |
| Abbott Laboratories | $335.19 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $303.77 | 2020-2024 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $287.71 | 2019-2024 | Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $279.09 | 2021-2024 | |
| Pfizer INC. | $155.08 | 2021-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $150.58 | 2022 | |
| Dexcom, INC. | $90.00 | 2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $75.99 | 2023-2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $65.56 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Corcept Therapeutics | $56.23 | 2021-2023 | Korlym |
| Novartis Pharmaceuticals Corporation | $54.20 | 2022-2023 | |
| Glaxosmithkline, LLC. | $33.13 | 2022-2024 | Trelegy Ellipta |
| Gilead Sciences, INC. | $32.08 | 2020-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $26.67 | 2024 | |
| Biogen, INC. | $24.35 | 2021 | |
| Daiichi Sankyo INC. | $24.02 | 2021 | |
| Acadia Pharmaceuticals INC | $22.85 | 2023 | Nuplazid |
| Abbvie INC. | $21.05 | 2022 | |
| Lucid Diagnostics INC. | $20.75 | 2022 | |
| Amag Pharmaceuticals, INC. | $20.39 | 2019 | |
| Eisai INC. | $20.19 | 2021 | |
| Dynavax Technologies Corporation | $19.46 | 2021 | |
| Tempus Ai, INC | $19.45 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $19.01 | 2021 | |
| Amneal Pharmaceuticals LLC | $16.74 | 2021 | |
| Medtronic, INC. | $14.19 | 2021 | |
| Ibsa Pharma INC. | $13.57 | 2019 | |
| Cranial Technologies, INC | $11.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philippe Chain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.